铝碳酸镁片联合埃索美拉唑肠溶片治疗幽门螺杆菌感染合并活动性胃溃疡的临床研究

发布时间：2018-06-07 20:33

本文选题：铝碳酸镁片 + 埃索美拉唑肠溶片　；参考：《中国临床药理学杂志》2017年19期

【摘要】：目的观察铝碳酸镁片联合埃索美拉唑肠溶片治疗幽门螺杆菌(Hp)感染合并活动性胃溃疡的临床疗效及安全性。方法将87例Hp感染合并活动性胃溃疡患者随机分为对照组44例和试验组43例。对照组予以埃索美拉唑肠溶片20 mg,qd,口服;试验组在对照组治疗的基础上,予以铝碳酸镁片每次1 g,tid,口服。2组患者均治疗4周。比较2组患者的临床疗效、Hp根除率、愈合质量,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为90.70%(39/43例)和88.64%(39/44例),Hp根除率分别为81.40%(35/43例)和77.27%(34/44例),差异均无统计学意义(均P0.05)。治疗后,试验组和对照组的愈合质量(优级)分别为65.12%(28/43例)和40.91%(18/44例),差异有统计学意义(P0.05)。试验组发生的药物不良反应有食欲缺乏、头晕、反胃,对照组发生的药物不良反应有食欲缺乏和反胃。试验组和对照组的总药物不良反应发生率分别为13.95%和11.36%,差异无统计学意义(P0.05)。结论铝碳酸镁片联合埃索美拉唑肠溶片治疗Hp感染合并活动性胃溃疡的临床疗效和安全性与单用埃索美拉唑肠溶片相似,但前者可显著提高患者溃疡的愈合质量。
[Abstract]:Objective to observe the efficacy and safety of magnesium bicarbonate tablets combined with esomeprazole enteric-coated tablets in the treatment of Helicobacter pylori infection with active gastric ulcer. Methods 87 patients with HP infection complicated with active gastric ulcer were randomly divided into control group (n = 44) and experimental group (n = 43). The control group was given esomeprazole enteric-coated tablet 20 mg / g QD, and the experimental group was given 1 g / d of magnesium bicarbonate on the basis of treatment in the control group. The patients in group 2 were treated for 4 weeks. The clinical efficacy, HP eradication rate, healing quality and adverse drug reactions were compared between the two groups. Results after treatment, the total effective rates of the test group and the control group were 90.70 / 39 / 43 and 88.64 / 39 / 44, respectively. The eradication rates of HP were 81.40 / 35 / 43) and 77.2727 / 34 / 44, respectively. There was no significant difference between the two groups (all P 0.05). After treatment, the healing quality (excellent grade) of the experimental group and the control group were 65.12 / 28 / 43 and 40.911 / 18 / 44, respectively. The difference was statistically significant (P 0.05). The adverse drug reactions in the trial group were appetite deficiency, dizziness, nausea, and those in the control group were appetite deficiency and nausea. The incidence of total adverse drug reactions in the trial group and the control group were 13.95% and 11.36%, respectively, with no significant difference (P 0.05). Conclusion the clinical efficacy and safety of bicarbonate tablets combined with esomeprazole enteric-coated tablets in the treatment of HP infection with active gastric ulcer are similar to those of esomeprazole enteric-coated tablets alone, but the former can significantly improve the healing quality of ulcer.
【作者单位】：中山大学附属第五医院消化内科;中山大学附属第五医院病理科;
【基金】：广东省科技厅科技计划基金资助项目(2016ZC0022)
【分类号】：R573.1

【相似文献】